NYSE MKT: SENS
 

Finally, the first and only CGM with an implantable sensor that lasts up to 90 days

Learn More Company Overview

SenseonicsTM

SENS

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' first generation continuous glucose monitoring (CGM) system, Eversense®, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels. For more information on Senseonics, please visit www.senseonics.com.

eversense Continuous Glucose Monitoring System

Introducing the latest advance in glucose monitoring. The Eversense CGM System includes an implantable sensor that lasts up to 90 days, a removable smart transmitter, and an easy-to-use mobile app. All wirelessly connected and designed to provide a new level of confidence and peace of mind in glucose monitoring.

About Us

Draco Financial LLC

Draco Financial is a corporate consulting and investor relations firm committed to creating long-term solutions for our featured companies. Our goal is to provide our client’s with the tools to succeed. Whether it’s capital to fund projects; strategic partnerships; recapitalizations; or information dissemination.

  Draco In Twitter